UCB (OTCMKTS:UCBJF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.
According to Zacks, “UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for central nervous system disorders, including epilepsy, diabetic neuropathic pain, sclerosis and Parkinson’s disease. It also provides therapy in the areas of oncology, immunology, inflammation, allergy and respiratory diseases. UCB delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. “
Shares of UCBJF stock opened at $80.31 on Friday. UCB has a fifty-two week low of $66.60 and a fifty-two week high of $86.75. The company has a market capitalization of $15,619.81, a price-to-earnings ratio of 23.14, a P/E/G ratio of 2.80 and a beta of -0.06.
ILLEGAL ACTIVITY NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/08/ucb-ucbjf-rating-lowered-to-hold-at-zacks-investment-research.html.
UCB Company Profile
UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. Its core products include Cimzia for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and Crohn's disease; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome.
Get a free copy of the Zacks research report on UCB (UCBJF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.